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Abstract
Background: Survival analysis methods such as the Kaplan-Meier method, log-rank test, and Cox proportional hazards 
regression (Cox regression) are commonly used to analyze data from randomized withdrawal studies in patients with 
major depressive disorder. However, unfortunately, such common methods may be inappropriate when a long-term 
censored relapse-free time appears in data as the methods assume that if complete follow-up were possible for all 
individuals, each would eventually experience the event of interest.
Methods: In this paper, to analyse data including such a long-term censored relapse-free time, we discuss a semi-
parametric cure regression (Cox cure regression), which combines a logistic formulation for the probability of 
occurrence of an event with a Cox proportional hazards specification for the time of occurrence of the event. In 
specifying the treatment's effect on disease-free survival, we consider the fraction of long-term survivors and the risks 
associated with a relapse of the disease. In addition, we develop a tree-based method for the time to event data to 
identify groups of patients with differing prognoses (cure survival CART). Although analysis methods typically adapt 
the log-rank statistic for recursive partitioning procedures, the method applied here used a likelihood ratio (LR) test 
statistic from a fitting of cure survival regression assuming exponential and Weibull distributions for the latency time of 
relapse.
Results: The method is illustrated using data from a sertraline randomized withdrawal study in patients with major 
depressive disorder.
Conclusions: We concluded that Cox cure regression reveals facts on who may be cured, and how the treatment and 
other factors effect on the cured incidence and on the relapse time of uncured patients, and that cure survival CART 
output provides easily understandable and interpretable information, useful both in identifying groups of patients with 
differing prognoses and in utilizing Cox cure regression models leading to meaningful interpretations.
Background
In a clinical study involving patients with major depres-
sive disorder (MDD), a long-term placebo treatment is
not acceptable due to an increased risk of suicide. In such
a situation, a randomized withdrawal design is one of the
most useful approaches for comparing the long-term effi-
cacy and safety of a drug and a placebo. A typical ran-
domized withdrawal study consists of an initial phase
during which all patients are given open-label active
treatment followed by randomization of the responders
to continued double-blind treatment with either active or
placebo treatment. The advantage of this study design is
the reduced duration of placebo treatment and an early-
escape endpoint, such as a relapse of signs or symptoms
of the disease or a lack of efficacy.
Table 1 provides a summary of the design and rates of
relapse in MDD patients from several recent randomized
withdrawal studies [1-5]. Common features among the
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Table 1: Study designs and relapse rates from several randomized withdrawal studies in patients with MDD
Source Study objectives, design and analysis Reported relapse rates
Rapaport et al. [1] Escitalopram continuation treatment to prevent relapse; a multi-center, 
placebo controlled, randomized withdrawal study; 36-week randomized 
treatment; Kaplan-Meier estimate and log-rank test as primary statistical 
analysis
Escitalopram 26.0%* (109)
Placebo 40.0%* (116)
Keller et al. [2] Long-term efficacy and tolerability of gepirone ER; a multi-center, placebo 
controlled, randomized withdrawal study; 40-44 weeks of randomized 
treatment; chi-square test; Kaplan-Meier estimate and log-rank test as 
Primary statistical analysis
Gepirone ER 20.6% (26/126)
Placebo 28.2% (35/124)
Kamijima et al.[3] Efficacy, safety and tolerability of sertraline in the prevention of relapse; a 
multicenter, placebo controlled, randomized withdrawal study; 16-week 
randomized treatment; Kaplan-Meier estimate and log-rank test as primary 
statistical analysis
Sertraline 08.5% (10/117)
Placebo 19.5% (23/118)
Perahia et al. [4] Efficacy, safety and tolerability of duloxetine in the prevention of relapse; A 
multi-center, placebo controlled, randomized withdrawal study; 26-week 
randomized treatment; Kaplan-Meier estimate, log-rank test as primary 
statistical analysis
Duloxetine 17.4% (23/132)
Placebo 28.5% (39/137)
Kocsis et al. [5] Long-term efficacy and safety of venlafaxine ER in preventing recurrence; a 
multi-center, placebo controlled, randomized withdrawal study; 12 
months randomized treatment; Kaplan-Meier estimate and log-rank test as 
primary statistical analysis
Venlafaxine ER 23.1%* (129)
Placebo 42.0%* (129)
* Determined by a Kaplan-Meier estimate as the number of patients with relapse was not reported in the article.
studies include long-term follow-up, relatively large sam-
ple size, high incidence of non-relapsed patients, and
non-excessive censoring from lost to follow-up during
the period when relapse events often occur. In addition,
the Kaplan-Meier method and log-rank test were most
often used to examine the efficacy of the test drug com-
pared with a placebo. The results from these randomized
withdrawal studies indicate that most individuals with
MDD often did not experience relapse events during the
treatment period. The proportion of non-relapse patients
ranged from 74.0% to 91.5% in the drug groups and 58.0%
to 80.5% in the placebo groups. The proportion of
patients who responded favourably to treatment, showing
no subsequent signs or sym ptoms of the disease, were
considered "cured", while the remaining patients may
eventually "relapse". As a result, a long-term censored
relapse-free time may appear in data. In this situation,
unfortunately, standard survival analysis methods such as
the log-rank test and Cox proportional hazards regres-
sion (Cox regression) may be inappropriate when analyz-
ing such long-term censored data, as they assume that if
complete follow-up were possible for all individuals, each
would eventually experience the event of interest.
In this paper, two methods of analysis were considered:
a semi-parametric cure regression (Cox cure regression)
and a tree-based method, known as survival CART (Clas-
sification And Regression Trees) [6]. The two methods
are generally used for the analysis of time-to-event cen-
sored data and may provide the findings different from
the standard Cox regression by assuming that there are
cured individuals in the data. The former method com-
bines a logistic formulation for the probability of occur-
rence of an event with a proportional hazards
specification for the time of occurrence of the event [7-
13], so that the effects of the treatment and other factors
can be interpreted separately into those on the propor-
tion of cured patients and the failure time of uncured
patients. In the latter method, termed cure survival
CART, the probability of occurrence of an event with the
exponential or Weibull distribution for the time of theArano et al. BMC Medical Research Methodology 2010, 10:33
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event occurrence is modelled using binary tree-structure.
Our approach was to incorporate the LR test statistic
from the fitting of the cure survival regressions for recur-
sive partitioning procedures, although the standard sur-
v i v a l  C A R T  m e t h o d  a d a p t s  t h e  m e t h o d  o f  C A R T
paradigm using the log-rank statistic [14]. Cure survival
CART was performed to supplement the results of Cox
cure regression and to provide a simple and useful inter-
pretation. These findings would provide valuable infor-
mation for the future treatment of patients with MDD.
This paper is structured as follows: first, we describe the
models, parameter estimations, and algorithms of the two
methods. We then illustrate some aspects of the two
methods, using data collected in a sertraline randomized
withdrawal study in patients with MDD [3], and end with
a discussion.
Methods
Cox cure regression
The model
Suppose that the data (Ti, Δi, Xi, Zi) are available for an
individual i = 1,..., n. Ti denotes the time to the occur-
rence of the event defined by min( , Ui), where   and
Ui are the random variables of true survival and censor-
ing, respectively. Δi denotes the censoring indicator Δi = I
( =  Ti), where I(·) is the indicator function. Xi and Zi
are the covariate vectors related to the cured incidence
and uncured survival, respectively.
Let λi(·) be the hazard function for an individual i. Sup-
pose that λi holds for the Cox proportional hazards model
if individual i is uncured and λi has zero-hazard other-
wise. Therefore, we can write
where λ0(t) is the baseline hazard function, β is the p-
dimensional parameter vector corresponding to Zi, and ηi
is the indicator ηi = 1 if individual i eventually experiences
the event (uncured) and ηi = 0 if individual i never experi-
ences the event, with the cured incidence ci = Pr(ηi = 0 |
Xi). Here we suppose that ci is the logistic model given by
where α is the q-dimensional parameter corresponding
to Xi, which usually consists of the form (1, Xi1,..., Xiq-1)T
with the intercept term Xi0 = 1.
Parameter estimation
In general, although observing ηi = 0 of being cured is not
possible, only ηi = 1 of being uncured when Δi = 1 is
known. For this reason, a marginal type of full likelihood
considered by Boag [15] is available for Cox cure regres-
sion. Then, the logarithm of the marginal full likelihood
for Cox cure regression is
where ,  Si(t) = exp[-exp(βT Zi)Λ0(t)]
and θ = (αT, βT)T
The estimate of (θ, Λ0) is obtained by maximizing lf
over (θ, Λ0). This maximization is performed using the
EM (Expectation-Maximization) algorithm, given a suit-
able stating value (θ(0), )  of  (θ, Λ0). We prepare a
suitable θ(0) using the Monte Carlo method [7,8]. Once we
have θ(0), a suitable   corresponding to θ(0) is com-
puted by a Newton-Raphson method discussed in Sugim-
oto and Hamasaki [13]. Although the optimization
technique based on the EM algorithm is computationally
fast, it easily fails to converge depending on starting val-
ues in Cox cure regression [10]. Therefore, providing an
appropriate (θ(0),  ) prudently in advance using these
methods, then we go ahead to the EM algorithm.
Using the concept of Taylor [16], the EM algorithm for
Cox cure regression has been developed [8-10]. The m-th
E-step in the EM algorithm transforms lf into the form for
the complete-data log likelihood
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for a given  ,
where  w(m)  is computed by current parameter values
 as   and
In the m  -th M-step algorithm, it is found that a
Breslow's estimate of Λ0 [17],
can be utilized for the maximization of
. Substituting   into Λ0
of   leads to a form of log partial likeli-
hood
Then, the M-step of   over (β, Λ0) is
replaced by maximizing   only over β  in
treating Λ0 as a nonparametric function. Therefore, the
M-step is easily performed by maximizing 
and   over  α and β, respectively, via a New-
ton-Raphson method.
Now, if θ(m)  = (α(m),  β(m) are the current estimates
obtained by the M-step for a given w(m), then current esti-
mate   of  Λ0 is written as  . For the
next (m +1) -th E-step, w(m) is updated to w(m+1) by substi-
tuting (θ(m, )  into  (θ, Λ0) in (1). Finally, ( ),
which provides 
becomes an estimate of (θ, Λ0) in a series of the EM-itera-
tion. From our limited experiences with real data and
simulation, it is recommended that a variety of starting
value θ(0) be used to ensure that a global maximum is
found. For further discussions, please see Sugimoto and
Goto [8], Peng and Dear [9], Sy and Taylor [10] and Sug-
imoto et al. [12]
Cure survival CART
In general, tree-based methods provide classifications of
patients with differing prognoses that may help clarify the
association of patient characteristics and survival. In this
section, a tree-based method for censored data including
long-term survivors is developed, based on cure survival
regression. With respect to the cost of calculations in
estimating the parameters, rather than the straightfor-
ward use of the semiparametric Cox cure regression dis-
cussed in the previous section, the fitting of parametric
cure regression is more reasonable, where the exponen-
tial distribution is assumed to be an underlying distribu-
tion for the latency time of relapse. However, since an
assumption of exponential distribution is restrictive, the
Weibull distribution is also considered. First, the model
will be described and then the algorithm will be dis-
cussed.
The model
It is assumed that the treated patient population is com-
posed of both cured and uncured patients. A sample con-
sists of vectors (Ti, Δi, Xi), i = 1,..., n, where (Ti, Δi, Xi) are
the same as the definitions in Cox cure regression. The
full likelihood of the tree constructed in this sample can
be described as
where   is a set of terminal nodes, {i: Xi ￿  } is a set
of individual labels which belong to node h, and   rep-
resents a covariate space which provides node h; λh(t), Sh
(t), and ch are the hazard function, survival function, and
cure rate, respectively, for the individuals in node h. For
the Weibull model, we write   and
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 with unknown parameters μh and
ρh, while the exponential case is reduced to those of ρ = 1.
wh (Ti) is the conditional probability that the i -th individ-
ual in node h will eventually belong to the uncured cate-
gory given that no event has occurred by time Ti, such
that
The major area of interest was the examining of cure
rates and the identification of MDD patients with differ-
ent prognoses. Parameter transformations such as log{ch/
(1 - ch)} = αh,   and   were adapted
and the EM algorithm, described in the previous section,
is used to estimate parameters ch,  μh and  ρh. For the
Weibull model, it is recommended that a suitable starting
point of ρh is sought in advance.
The algorithm
The tree-based method requires the splitting, pruning,
and selection of a pruned subtree to be specified [6].
Since high-dimensional data may give a complicated tree-
structure, the following specifications were considered to
simplify the tree structure, and the results were subse-
quently interpreted.
Splitting Two disjointed tree-based graphs are developed
by recursively splitting data into two regions. Each split is
evaluated for each of the variables, and a single variable
(Xi) and the split value resulting in the greatest reduction
in impurity is selected by likelihood-ratio test statistic of
cure exponential regression, to best reduce error. When
growing trees, the improvement measure for a split (s) at
node h into left and right daughter nodes, l (h) and r (h),
respectively, is measured by R(s, h) = R (h) - {R(l (h))R +r
(h)}, where)
represents the -2 times maximum log likelihood
divided by the sample size n (deviance residual) obtained
for the data of node ħ = (= h, l(h), r (h)); ,    and 
are the maximum likelihood estimates (MLEs) of cħ, μħ
and ρħ obtained for node ħ,
In the exponential case,   holds and the hazard
function is simply expressed as
A split   satisfying   over s ￿
 is selected, where the set   is composed of all possi-
ble binary splitting rules considered at node h. The two
new daughter nodes, l (h) and r (h), determined by 
are generated, and the tree as a whole grows. Such a gen-
eration of nodes is performed successively at any node
until a pre-specified stopping condition (e.g., the maxi-
mal number of terminal nodes or the minimal number of
observations in terminal nodes) is satisfied.
Pruning The "Pruning procedure" [6] determines the
order how to remove superfluous sub-trees of a largest
tree   to build a good fitting simple tree-based
model. This process is repeated until only a small fraction
of the data remains. The final tree expresses a logical rule
representing an extreme outcome group.
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Methods based on within-node deviance are hired for
pruning. In the CART algorithm, the performance of a
tree is based on the cost complexity measure, defined by
For the binary tree,   is the number of terminal
nodes, and γ is a penalty per terminal node  . A sub-
tree (a tree obtained by removing branches)   (γ) is the
smallest optimally pruned sub-tree for any penalty γ of
the largest tree   if
where   indicates that   is a sub-tree of
; and   is the smallest optimally pruned sub-
tree such that   for every optimally pruned sub-
tree .
The cost complexity pruning algorithm allows the opti-
mally pruned sub-tree for any γ to be obtained. This algo-
rithm finds the sequence of optimally pruned sub-trees
 by repeatedly
deleting branches of the tree for which the average reduc-
tion in impurity per split in the branch is smallest, where
The pruning algorithm is necessary for finding optimal
sub-trees because the number of possible sub-trees grows
very rapidly as a function of tree size.
Selection of a pruned sub-tree The selection of a
pruned sub-tree can be based on a re-sampling technique
(cross-validation) to correct for over-optimism due to
split point optimization [6]. The most popular method
for obtaining tree-based estimates of prediction error (or
expected deviance) is V-fold cross-validation. The data
 are divided up into V  sets   and subsamples
 of about equal size, and trees 
are grown from the subsamples  . For any γ, an opti-
mally pruned sub-tree  (γ) and MLEs
 and   in   are obtained.
The average cross-validated deviance residual over V
subsamples is
Let  γk*  be the value of that minimizes Rcv(γ) of
, k = 0,1,2,. Then a tree   cor-
responding to γk* is selected.
We adopt V = 10 because a smaller value of V is pre-
ferred to V = n in the application of CART [18]. While 10-
fold cross-validation is a standard method for selecting
tree size, it is subject to considerable variability. There-
fore, in the application to this data, we performed 500
replications of 10-fold cross-validation and then deter-
mined  γk*  to minimize the average of 500 pairs of
.  W e  w i l l  b e  a b l e  t o
use the "1-SE (Standard Error)" rule [6] to choose a sim-
pler tree, where such an SE is directly estimated by the
variation of Rcv (γ) with 500 replications in this applica-
tion.
Results
Study design and major results of a sertraline randomized 
withdrawal study
A multicenter, placebo-controlled, randomized with-
drawal study was used to evaluate the efficacy and safety
of sertraline in Japanese patients with MDD [3]. Follow-
ing a 1-week observational period for washout, only those
patients who responded after 8 weeks of open-label ser-
traline treatment were randomly assigned to receive one
of two subsequent 16-week double-blind treatments with
sertraline or a placebo. Patients who did not respond
after 8 weeks of the open-label treatment were discontin-
ued from the study. The primary variable was a relapse of
the disease during the double-blind phase, which was
defined as either (i) having a score of Hamilton rating
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scale for depression (HAM-D) (17 items) of 18 point or
greater and a clinical global impression (compared to
baseline of the open-label phase) of "no-change" or
"worse", during two consecutive visits, or (ii) being unable
to continue treatment due to insufficient efficacy.
A total of 415 patients were screened, of which 361
received sertraline in the open-label phase of the study.
From this group, a total of 235 were randomized to the
sertraline (ns  = 117) or placebo (np  = 118) treatment
groups during the double-blind phase. All analyses were
based on the intent-to-treat principle. Relapse rates of
8.5% (10 of 117) and 19.5% (23 of 118) in the sertraline
and placebo treatment groups, respectively were
observed, which represented a statistically significant dif-
ference (Chi-squared test: p = 0.0158). Examination of
the time to relapse using the Kaplan-Meier methods
showed that the relapse-free rate curve for the sertraline
treatment group was significantly higher than in placebo
treatment group throughout the double-blind phase (log-
rank test: p = 0.0261) (Figure 1). For more details, please
refer to Kamijima et al. [3].
The standard logistic and Cox regressions were used to
identify the effect of variables on the incidence of cured
and uncured patients, which were not given in Kamijima
et al. [3]. Each model included the treatment (Sertraline =
1), baseline HAM-D score at open-label phase (OP),
baseline HAM-D score at double-blind phase (DP), gen-
der (Female = 1), age, the number of episodes, duration
from the first episode, duration of this episode, interval
from the previous episode, and complication of MDD
(complication) (Yes = 1) as covariates (Table 2). The
results from both analyses suggest significant effects of
treatment and gender on relapse events and time to
relapse.
Application of Cox cure regression and cure survival CART 
to sertraline data
Cox cure regression, including influential covariates for
both cured incidence and uncured survivals, provides
flexibility in model building. However, this approach may
open discussions on the possibility of an overparameter-
ization of models and the identifiability between the
parameters of cured incidence and uncured survivals
[10], although the parameters of the standard cure model
are identifiable in some sense [19]. In our situation, there
was more scientific and practical interest in estimating
the cured incidence as the objective of the study was to
show how well the drug prevents an eventual episode of
recurring illness (cured incidence), compared with pla-
cebo and, further, how other covariates influence cured
incidence. Thus, in selecting the covariates, we consid-
ered that, giving priority to cured incidence over uncured
survivals, a minimal number or no covariate in uncured
survivals may be appropriate, and then we suggested the
following guidelines on variable selection in our situation:
(1) treatment is always factored into cured incidence, (2)
either a minimal number or no covariates are included
into uncured survivals, (3) a covariate already included
into cured incidence is not included into uncured surviv-
als. Following these guidelines, the "best" subset of all
possible combinations of covariates can be selected by a
minimum value of Akaike's information criterion (AIC)
[20], given by   is (θ,
Λ0) that maximizes lf (θ, Λ0), discussed in the previous
Methods section.
The result of Cox cure regression after variable selec-
tion is summarized in Table 3. The value of AIC sug-
gested the best subset of treatment and baseline HAM-D
score at DP, which were included into cured incidence,
and gender and complication were included into uncured
survivals. For the cured incidence, the positive estimate
for treatment indicated a higher cure rate for patients
who received sertraline treatment, while the negative
estimate for baseline HAM-D score at DP indicated a
lower cured incidence for patients with a higher value of
the score. In contrast, for uncured survivals, the positive
estimate for gender indicated an earlier occurrence of
relapse for female patients, and the negative estimate for
complication indicated a prolonged occurrence of relapse
for patients with any complications of MDD.
T h e  r e s u l t  o f  b e s t  s u b s e t  o f  c o v a r i a t e s  f o r  s t a n d a r d
logistic and Cox regressions with the minimum value of
A I C  i s  s h o w n  i n  T a b l e  4 .  S t a n d a r d  l o g i s t i c  a n d  C o x
regressions suggested the effects of treatment and gender,
which were in agreement with the result of Cox cure
regression. In addition to the baseline HAM-D score at
DP and complication, the standard logistic regression
indicated a weak effect on the number of episodes. On
the other hand, standard Cox regression was not able to
detect the effect of baseline HAM-D score at DP, but it
indicated a weak effect on the number of episodes. This
was a major discrepancy between Cox cure regression
and standard Cox regression. Compared with the best
subset of covariates of standard logistic and Cox regres-
sions, Cox cure regression suggested the covariates that
were more important for cured incidence but less impor-
AIC l p q f =− + +
∧∧ ∧∧
22 00 (, ) ( ) ; (, ) q qq q ΛΛArano et al. BMC Medical Research Methodology 2010, 10:33
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tant for the uncured survivals, and vice versa. The subset
for Cox cure regression provided a smaller value of AIC
than that of standard Cox regression. The standard Cox
regression is a special case of Cox cure regression with an
infinitely small intercept in cured incidence [10]. The
estimate and SE for the intercept were 1.571 and 2.870,
respectively. These results support the use of Cox cure
regression rather than standard Cox regression.
N e x t ,  t h e  c u r e  s u r v i v a l  C A R T  w a s  u s e d  t o  i d e n t i f y
groups of patients with differing prognoses, and to refine
the model previously obtained by Cox cure regression
with meaningful interpretation. Four covariates (treat-
ment, baseline HAM-D score at DP, gender and compli-
cation), which were identified by Cox cure regression,
were selected to characterize the time to relapse for the
sertraline data. In the application of the cure survival
CART with exponential distribution, based on the aver-
age of 500 replications, the minimum cross-validated
deviance residual was Rcv (γk*) = 1.753 (SE = 0.083), and
the corresponding tree   was quite large. The 1-SE
rule was used to choose a simpler tree, shown in Figure 2,
which provides the cross-validated estimate of Rcv (γ) =
1.791. Similarly, for the cure survival CART with Weibull
distribution, the minimum cross-validated estimate
based on the average of 500 replications is Rcv (γk*) = 1.981
(SE = 0.229), and the corresponding tree   is shown in
Figure 3. As seen in Figure 2, the cure survival CART with
exponential distribution showed that the primary split
was gender and the secondary was treatment for the sub-
group of female patients. Further partitioning of the tree
k*
k*
Figure 1 Kaplan-Meier estimates for time to relapse in the sertraline and placebo treatment groups.
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was based on the baseline HAM-D score at DP of 6 points
for the subgroup of female patients assigned to the sertra-
line treatment group. On the other hand, as seen in Fig-
ure 3, the cure survival CART with Weibull distribution
provided a simpler tree structure compared with that
seen in the cure survival CART with exponential distri-
bution; there was no partitioning of the tree based on the
baseline HAM-D score at DP for the subgroup of female
patients assigned to the sertraline treatment group. By
comparison with the cross-validated estimates between
exponential and Weibull distributions, we could find that
Table 2: Result of standard logistic and Cox regressions to a sertraline randomized withdrawal study in patients with MDD
95% CI
Standard logistic regression Estimates SE Lower Upper p-value
Intercept 1.686 1.687 -1.621 4.992 0.3178
Treatment 0.968 0.429 0.152 1.848 0.0239
Baseline HAM-D score at OP 0.007 0.062 -0.111 0.134 0.9096
Baleline HAM-D score at DP -0.100 0.068 -0.240 0.029 0.1443
Gender -1.842 0.575 -3.123 -0.817 0.0014
Age 0.026 0.020 -0.013, 0.068 0.2020
The number of episodes 0.174 0.139 -0.016 0.531 0.2111
Duration from the 1st episode -0.002 0.003 -0.008 0.005 0.5575
Duration of this episode -0.002 0.022 -0.041 0.046 0.9296
Interval from the previous episode 0.004 0.007 -0.008 0.019 0.5553
Complication 0.572 0.413 -0.241 1.388 0.1654
Maximum log-likelihood -81.603
AIC 185.206
95% CI
Standard Cox regression Estimates SE Lower Upper p-value
Treatment -0.845 0.388 -1.604 -0.086 0.0293
Baseline HAM-D score at OP 0.005 0.053 -0.099 0.109 0.9222
Baseline HAM-D score at DP 0.063 0.059 -0.052 0.180 0.2847
Gender 1.639 0.543 0.575 2.702 0.0025
Age -0.023 0.018 -0.058 0.012 0.1977
The number of episodes -0.152 0.130 -0.406 0.102 0.2399
Duration from the 1st episode 0.002 0.003 -0.004 0.007 0.5729
Duration of this episode 0.005 0.019 -0.033 0.042 0.8038
Interval from the previous episode -0.003 0.006 -0.014 0.009 0.6274
Complication -0.518 0.358 -1.221 0.184 0.1482
Maximum log-likelihood* -180.917
AIC 381.834
* maximum full log-likelihoodArano et al. BMC Medical Research Methodology 2010, 10:33
http://www.biomedcentral.com/1471-2288/10/33
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the cure survival CART with exponential distribution
provided a better fit than that with Weibull distribution.
From the results obtained by the two cure survival
CARTs, refined Cox cure regression was reperformed;
the model included treatment, the baseline HAM-D
score at DP and the interaction between the treatment
and the baseline HAM-D score at DP into cured inci-
dence, and gender and complication into uncured surviv-
als. The baseline HAM-D score at DP was categorized
into two groups: baseline HAM-D score at DP >6 ( = 1)
and baseline HAM-D score at DP ≤ 6 (= 0).
The result of refined Cox cure regression is shown in
Table 5. For cured incidence, a major difference between
original and refined Cox cure regressions was a signifi-
cant effect of the interaction between the treatment and
the categorized baseline HAM-D score at DP. Refined
Cox cure regression provided the negative estimates for
the interaction, which indicated a higher cure rate for
patients with a lower value of the score who received ser-
traline treatment, but a lower cure rate for patients with a
higher value of the score who received the placebo. For
uncured survival, there was no major difference between
the original and refined Cox cure regressions. Also, as
refined Cox cure regression provided a smaller AIC value
than original Cox cure regression, refined Cox cure
regression would lead to an improved fit. Figure 4 shows
estimated curves for the time to relapse for each combi-
nation of the treatment and categorized baseline HAM-D
score at DP, adjusted by gender and complication, using
refined Cox regression. The important differences in
cured incidence were observed between the sertraline
and placebo groups with regard to the baseline HAM-D
score.
Discussion
The results obtained by Cox cure regression and cure
exponential CART agree with findings reported by sev-
eral authors [21-23]. For example, Nierenberg et al. [23]
reported that a greater number of residual symptoms and
higher HAM-D scores are associated with a higher prob-
ability of relapse. Although there are several inconsisten-
cies regarding the gender difference in the course of the
relapse, Kuehner [21] reported that female patients have a
higher risk of earlier occurrence of relapse. In addition,
co-morbidity of MMD with other illnesses has been
widely reported [22]. The variable of complication used
in the analysis was a binary variable of "yes" or "no", but
original data included more detailed information on the
n u m b e r  a n d  t y p e  o f  c o m p l i cations for each patient.
Therefore, further investigation on the effect of the num-
ber and type of complications on uncured survivals (or
cured incidence) is necessary. Furthermore, the cut-off
point for the baseline HAM-D score at DP at 6 points
suggested by cure survival CART was nearly equal to the
HAM-D definition of full remission (a score of 7 points or
less). It is generally considered that the final goal of treat-
ment for MDD is to achieve and maintain remission and
the prevention of relapse.
Cox cure regression (or survival cure CART) generally
requires a long-term follow-up [10,24]. The sertraline
study discussed in this paper was intended to contribute
to a new drug application in Japan, so the length of the
follow-up period (16 weeks) in the study was minimized
Table 3: Result of best subset for Cox cure regression
95% CI
Cured incidence Estimates SE Lower Upper p-value
Intercept 1.571 2.870 -4.053 7.196 0.5840
Treatment 1.177 0.429 0.335 2.018 0.0061
Baseline HAM-D score at DP -0.122 0.071 -0.262 0.018 0.0869
95% CI
Uncured survivals Estimates SE Lower Upper p-value
Gender 1.953 0.535 0.905 3.001 0.0003
Complication -0.967 0.418 -1.798 -0.159 0.0193
Maximum log-likelihood -179.578
AIC 369.155Arano et al. BMC Medical Research Methodology 2010, 10:33
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to merely detect the drug's effect, in order to reduce the
duration of unnecessary exposure of patients to the drug
or placebo. However, in the application of Cox cure
regression to real data, before the formal analysis, an
assessment of whether or not the length of follow-up is
sufficient would be useful for interpreting the result. To
confirm this for the sertraline data, the qn-test discussed
by Maller and Zhou [24] was performed for the sertraline
and placebo groups, constructed by the estimated cure
rates and censoring distribution for this data. For the ser-
traline group, the observed value of 0.08547 of qn was
between 94% and 96% critical points of the test, which
Table 4: Result of best subset for standard logistic and Cox regressions
95% CI
Standard logistic regression Estimates SE Lower Upper p-value
Intercept 2.865 0.848 1.203 4.527 0.0007
Treatment 1.021 0.421 0.196 1.846 0.0153
Baseline HAM-D score at DP -0.107 0.066 -0.236 0.222 0.1036
Gender -1.737 0.563 -2.841 -0.633 0.0021
The number of episodes 0.133 0.114 -0.091 0.357 0.2443
Complication 0.585 0.407 -0.213 1.384 0.1507
Maximum log-likelihood -81.868
AIC 177.736
95% CI
Standard Cox regression Estimates SE Lower Upper p-value
Treatment -0.913 0.379 -1.655 -0.171 0.0159
Gender 1.511 0.534 0.465 2.557 0.0046
The number of episodes -0.131 0.109 -0.345 0.083 0.2296
Maximum log-likelihood* -183.520
AIC 373.040
* maximum full log-likelihood
Figure 2 Tree structure determined by cure survival CART analy-
sis with exponential distribution.
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Figure 3 Tree structure determined by cure survival CART analy-
sis with Weibull distribution.
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supported that the length of follow-up for the sertraline
group was acceptably minimal and the data had levelled
off. On the other hand, for the placebo group, the
observed value of 0.0085 of qn was much smaller than the
value of 0.068 for the 95% point, which did not support
that the length of follow-up for the placebo group was
sufficient and that the data had levelled off. According to
the results of two qn-tests, we could conclude that the
length of follow-up period in the sertraline study was suf-
ficient at least to detect the drug's effect compared with
placebo.
In variable selection for the fitting of Cox cure regres-
sion to the sertraline data, we gave priority to cured inci-
dence over uncured survivals. However, if there was more
scientific interest in when the illness may recur rather
than in the eventual cure, giving priority to uncured sur-
vivals over cured incidence could be appropriate. There
are several aspects of variable selection, depending on the
applications of interest.
In the paper, we discussed the two methods of cure Cox
regression and cure survival CART. As described in
Method section, the former method is a semiparametric
regression, but the latter method use a parametric cure
regression. Although the cure survival CART output pro-
vided information in refining Cox cure regression leading
to meaningful interpretations for the sertraline data, note
that there is the potential inconsistency between the two
regressions when they consider both for data as the esti-
mates from the semiparametric Cox cure regression and
those from the parametric Cox cure regression are usu-
ally sensitive to the baseline distribution assumption. Our
future challenge is to develop the semiparametric cure
survival CART with fewer amounts of computations.
Conclusions
In this study, a semi-parametric cure regression was used
to investigate the latency time of recurrence observed in a
sertraline randomized withdrawal study in patients with
MDD. In specifying the treatment's effect on disease-free
survival, account was taken of the fraction of long-term
survivors and the risks associated with the relapse of the
disease. In addition, a tree-based method, i.e., the cure
survival CART, was used to analyze the time to event data
in order to identify groups of patients with differing prog-
Table 5: Result of refined Cox cure regression
95% CI
Cured incidence Estimates SE Lower Upper p-value
Intercept 0.753 1.374 -1.940 3.447 0.5835
Treatment 30.954 10.001 11.353 50.555 0.0020
Baseline HAM-D score at DP -0.233 0.646 -1.449 1.033 0.7183
Treatment × Baseline HAM-D score at DP -30.180 13.497 -56.634 -3.725 0.0254
95% CI
Uncured survivals Estimates SE Lower Upper p-value
Gender 1.926 0.535 0.878 2.974 0.0003
Complication -0.895 0.469 -1.814 0.024 0.0563
Maximum log-likelihood -177.499
AIC 366.998
Figure 4 Estimated curve for the time to relapse by refined Cox 
cure regression.Arano et al. BMC Medical Research Methodology 2010, 10:33
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noses. The following are the main findings: (1) Cox cure
regression reveals facts on who may be cured, and how
the treatment and other factors effect on the cured inci-
dence and on the relapse time of uncured patients. (2)
Cure survival CART output provides easily understand-
able and interpretable information, useful both in identi-
fying groups of patients with differing prognoses and in
utilizing Cox cure regression leading to meaningful inter-
pretations.
The methods discussed in this paper could be applied
to the development of stratification schemes for future
clinical studies and the identification of patients suitable
for studies involving therapy targeted at a specific prog-
nostic group. T his is would be beneficial as it is often
desirable to understand the correlation between a
patient's characteristics and relapse times to aid in the
design of clinical studies.
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